After concentrating on artificial intelligence for his MS degree in computer science from Tufts University, Max Alexander spent the next seven years developing automated bioinformatics research tools at the world-renowned Dana-Farber Cancer Institute’s Blais Proteomics Center. While his work was critical to help speed research on small-molecule drugs targeting various cancers, he learned that biological drugs involving DNA and RNA would supercede his research focus. He became intrigued with the idea of sequence design as a therapeutic, and when he saw Kernal’s approach, the fit seem right. Obviously, it didn’t hurt that mRNA is one of the most hyped technologies on the planet right now, given the amazing success of the Pfizer and Moderna vaccines. Max came to Kernal from Radix Labs, where he developed multiple components of the its platform for coordinated biological laboratory automation. What does Max do when he needs a break from optimizing Kernal’s machine learning tools for hyper-selective delivery and hyper-selective activation of mRNA? He’s on his computer playing video games, or out hiking in nature, away from all screens.